Bifikafusp alfa/onfekafusp alfa

Last updated

Bifikafusp alfa/onfekafusp alfa
Combination of
Bifikafusp alfa Protein
Onfekafusp alfa Protein
Clinical data
ATC code

Bifikafusp alfa/onfekafusp alfa is a experimental cancer treatment intended for the treatment of melanoma. [1] It contains bifikafusp alfa and onfekafusp alfa. [1]

Bifikafusp alfa consists of interleukin-2 (IL-2), a naturally occurring protein that activates certain white blood cells that can recognize and attack cancer cells. [1] Bifikafusp alfa is linked to L19, another protein which was expected to enable the medicine to target cancer cells and not healthy tissue. [1] [2] Onfekafusp alfa consists of tumor necrosis factor which disrupts the blood supply to the tumor, and is also linked to L19. [1] [3]

In June 2025, Philogen S.p.A. withdrew its application in the European Union for a marketing authorization of Nidlegy for the treatment of melanoma, a type of skin cancer. [1]

References

  1. 1 2 3 4 5 6 "Nidlegy EPAR". European Medicines Agency (EMA). 25 July 2025. Retrieved 27 July 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ↑ "Bifikafusp Alfa ( Code - C166577 )". EVS Explore. Retrieved 27 July 2025.
  3. ↑ "Onfekafusp Alfa ( Code - C166939 )". EVS Explore. Retrieved 27 July 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.